Article

The economic impact of Attention-Deficit/Hyperactivity disorder in children and adolescents

University of North Carolina at Chapel Hill, North Carolina, United States
Journal of Pediatric Psychology (Impact Factor: 2.91). 08/2007; 32(6):711-27. DOI: 10.1093/jpepsy/jsm022
Source: PubMed

ABSTRACT Using a cost of illness (COI) framework, this article examines the economic impact of attention-deficit/hyperactivity disorder (ADHD) in childhood and adolescence. Our review of published literature identified 13 studies, most conducted on existing databases by using diagnostic and medical procedure codes and focused on health care costs. Two were longitudinal studies of identified children with ADHD followed into adolescence. Costs were examined for ADHD treatment-related and other health care costs (all but 1 study addressed some aspect of health care), education (special education, 2 studies; disciplinary costs: 1 study), parental work loss (2 studies), and juvenile justice (2 studies). Based on this small and as yet incomplete evidence base, we estimated annual COI of ADHD in children and adolescents at $14,576 per individual (2005 dollars). Given the variability of estimates across studies on which that number is based, a reasonable range is between $12,005 and $17,458 per individual. Using a prevalence rate of 5%, a conservative estimate of the annual societal COI for ADHD in childhood and adolescence is $42.5 billion, with a range between $36 billion and $52.4 billion. Estimates are preliminary because the literature is incomplete; many potential costs have not been assessed in extant studies. Limitations of the review and suggestions for future research on COI of ADHD are provided.

1 Bookmark
 · 
85 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Overwhelming evidence suggests that a diagnosis of attention deficit/hyperactivity disorder (ADHD) in childhood has profound and far-reaching effects on children's functioning in the school environment. In this article, we draw on a wide range of research studies to summarize the state of our knowledge about the academic functioning of children with ADHD and discuss intervention approaches that align with these areas. We use ecological systems theory to outline the various factors that are related to school functioning for children with ADHD at the child, classroom, and family levels. We place a particular emphasis on the importance of high-quality relationships within the delivery of interventions and highlight the need for sustainable, collaborative, and contex-tual interventions if we are to meet the complex and heterogeneous needs of children with ADHD in the school setting.
    02/2015; 2(1). DOI:10.1007/s40474-015-0038-6
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Polycyclic aromatic hydrocarbons are widespread urban air pollutants from combustion of fossil fuel and other organic material shown previously to be neurotoxic.
    PLoS ONE 11/2014; 9(11):e111670. DOI:10.1371/journal.pone.0111670 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objectives There is a lack of comparative effectiveness research among Attention deficit hyperactivity disorder (ADHD) drugs in terms of efficacy and acceptability, where bupropion is compared with atomoxetine, lisdexamfetamine and methylphenidate. The main aim of this work was to compare the efficacy and acceptability of these drugs in children and adolescents using a metaanalysis. Methods A literature search was conducted to identify double-blind, placebo-controlled, noncrossover studies of ADHD. PubMed/Medline and Clinicaltrials.gov were searched. Comparative drug efficacy to placebo was calculated based on the standardized mean difference (SMD), while the comparative drug acceptability (all cause discontinuation) to placebo was estimated on the odds ratio (OR). Results In total 28 trials were included in the meta-analysis. Efficacy in reducing ADHD symptoms compared to placebo was small for bupropion (SMD = -0.32, 95% CI; -0.69, 0.05), while modest efficacy was shown for atomoxetine (SMD = -0.68, 95% CI; -0.76, -0.59) and methylphenidate (SMD = -0.75, 95% CI; -0.98, -0.52) and high efficacy was observed for lisdexamfetamine (SMD = -1.28, 95%CI; -1.84, -0.71). Compared to placebo treatment discontinuation was statistically significantly lower for methylphenidate (OR=0.35, 95% CI; 0.24, 0.52), while it was not significantly different for atomoxetine (OR = 0.91, 95% CI; 0.66, 1.24), lisdexamfetamine (OR = 0.60, 95% CI, 0.22, 1.65), and bupropion (OR = 1.64, 95% CI; 0.5, 5.43). Limitations The heterogeneity was high, except in atomoxetine trials. The crossover studies were excluded. The effect sizes at specific time points were not computed. Studies with comorbid conditions, except those reporting on oppositional defiant disorder, were also excluded. All studies involving MPH were combined. Conclusions The results suggest that lisdexamfetamine has the best benefit risk balance and has promising potential for treating children and adolescents with ADHD. More research is needed for a better clinical evaluation of bupropion.
    Journal of Affective Disorders 03/2015; DOI:10.1016/j.jad.2015.03.006 · 3.76 Impact Factor